Jorge Martin Arana (@kokemartin) 's Twitter Profile
Jorge Martin Arana

@kokemartin

PhD at the Oncology Unit of the INCLIVA Biomedical Research Institute. Bioinformatician, biotechnologist and a friend :)

ID: 489615304

calendar_today11-02-2012 18:16:59

1,1K Tweet

205 Followers

270 Following

Noelia Tarazona (@tarazonanoelia) 's Twitter Profile Photo

🔥Just out in Nature Cancer! ✅ TAV16, our tumor-agnostic WES-based assay, ranks among the best for MRD detection. ✅ Immune evasion as the main driver progression in MSS CRC, opening new avenues for ICIs. 🙏SEOM Grupo Español de Tratamiento de Tumores Digestivos Instituto de Salud Carlos III (ISCIII) Hospital Clínic de València nature.com/articles/s4301…

Jorge Martin Arana (@kokemartin) 's Twitter Profile Photo

Thrilled to share our latest work in Nature Cancer! 🔥 Key findings in CRC:  🎯 TAV16, a ctDNA tumor-agnostic assay improves MRD detection  🛡️ Immune evasion identified as a key progression mechanism Read more: nature.com/articles/s4301… #CRC #ctDNA #MRD INCLIVA Hospital Clínic de València

INCLIVA (@incliva_iis) 's Twitter Profile Photo

🗞️ Una investigación pionera de INCLIVA mejora la detección de micrometástasis del cáncer de colon mediante un análisis de sangre y abre las puertas a la inmunoterapia en fases tempranas 🔗 incliva.es/una-investigac…

🗞️ Una investigación pionera de INCLIVA mejora la detección de micrometástasis del cáncer de colon mediante un análisis de sangre y abre las puertas a la inmunoterapia en fases tempranas

🔗 incliva.es/una-investigac…
Radio Valencia SER (@radiovalencia) 's Twitter Profile Photo

Investigadores del INCLIVA mejoran la detección de micrometástasis en cáncer de colon mediante un análisis de sangre cadenaser.com/comunitat-vale…

Generalitat (@generalitat) 's Twitter Profile Photo

👩‍🔬🧫 Una investigació liderada per INCLIVA millora la detecció de micrometàstasi del càncer de còlon 🆕 Estudi pioner ✅ Permetrà ⤵ 💊 noves vies terapèutiques, com l'ús d'immunoteràpia en fases primerenques 🩺 identificar la malaltia mínima residual després de la

👩‍🔬🧫 Una investigació liderada per <a href="/incliva_iis/">INCLIVA</a> millora la detecció de micrometàstasi del càncer de còlon

🆕 Estudi pioner

✅ Permetrà ⤵
💊 noves vies terapèutiques, com l'ús d'immunoteràpia en fases primerenques
🩺 identificar la malaltia mínima residual després de la
Intestinal Cell News (@intestinal_cell) 's Twitter Profile Photo

🧬 Dr. Jorge Martín-Arana (Jorge Martin Arana) and team at INCLIVA performed whole-exome sequencing of ctDNA at different time points in participants with relapsed colon cancer in two independent cohorts. 🔓 Nature Cancer | go.nature.com/4iH5ueq

🧬 Dr. Jorge Martín-Arana (<a href="/KokeMartin/">Jorge Martin Arana</a>) and team at <a href="/incliva_iis/">INCLIVA</a> performed whole-exome sequencing of ctDNA at different time points in participants with relapsed colon cancer in two independent cohorts.

🔓 <a href="/NatureCancer/">Nature Cancer</a> | go.nature.com/4iH5ueq
Informativos Telecinco (@informativost5) 's Twitter Profile Photo

Una investigación liderada por el Hospital Clínico de Valencia mejora la detección de micrometástasis del cáncer de colon ver.tw/auqb12

Noelia Tarazona (@tarazonanoelia) 's Twitter Profile Photo

Un test ideado en España permite detectar qué pacientes de cáncer de colon recaerán tras la cirugía elperiodico.com/es/sanidad/202… a través de El Periódico

Informativos Telecinco (@informativost5) 's Twitter Profile Photo

Nuevo avance científico marca España: un test de sangre permitirá detectar el riesgo de recaída del cáncer colorrectal ver.tw/dcwrq2

Noelia Tarazona (@tarazonanoelia) 's Twitter Profile Photo

💥Proud of our team for presenting cutting-edge work on ctDNA🩸and tumor-immune profiling in CRC at #EACR2025! 🔬From resistance mechanisms to new immunotherapy strategies - science made in Valencia INCLIVA 🇪🇸✨ 🔝Belén Martínez Castedo Daniel González Camblor Blanca García Micó

💥Proud of our team for presenting cutting-edge work on ctDNA🩸and tumor-immune profiling in CRC at #EACR2025! 

🔬From resistance mechanisms to new immunotherapy strategies - science made in Valencia <a href="/incliva_iis/">INCLIVA</a> 🇪🇸✨
🔝<a href="/_belenmartinez/">Belén Martínez Castedo</a> <a href="/dgcamblor/">Daniel González Camblor</a> <a href="/GarciaMicoB/">Blanca García Micó</a>
Noelia Tarazona (@tarazonanoelia) 's Twitter Profile Photo

🔥 We got the cover of the June issue of Nature Cancer with our paper! 🌟 A huge honor and a recognition of the team’s hard work. 🔗 lnkd.in/dd6dE7A4 📄 See lnkd.in/dfd3hfi2

🔥 We got the cover of the June issue of <a href="/NatureCancer/">Nature Cancer</a> with our paper! 🌟 A huge honor and a recognition of the team’s hard work.

🔗 lnkd.in/dd6dE7A4

📄 See lnkd.in/dfd3hfi2
Mario Balsa (@mariobalsamd) 's Twitter Profile Photo

📢 New in Nature Cancer: WES-based tumor-agnostic ctDNA analysis improves MRD detection & reveals immune escape as key in localized colon cancer relapse. nature.com/articles/s4301… 🎯 Precision meets persistence. MRD, meet your nemesis. Congrats to Jorge Martin Arana Noelia Tarazona and

Noelia Tarazona (@tarazonanoelia) 's Twitter Profile Photo

🔥New in Nature Genetics by Francisco Gimeno-Valiente during his postdoc at UCL under Nnennaya Kanu Charles Swanton 🔝 📌Genomic & epigenomic drivers converge in lung cancer. New methylation dN/dS + AllChAT reveal chromatin-driven dosage compensation. 🔗nature.com/articles/s4158…

🔥New in <a href="/NatureGenet/">Nature Genetics</a> by <a href="/F_gimenoval/">Francisco Gimeno-Valiente</a> during his postdoc at <a href="/ucl/">UCL</a> under <a href="/NnennayaKanu/">Nnennaya Kanu</a> <a href="/CharlesSwanton/">Charles Swanton</a> 🔝

📌Genomic &amp; epigenomic drivers converge in lung cancer. New methylation dN/dS + AllChAT reveal chromatin-driven dosage compensation.
🔗nature.com/articles/s4158…
Noelia Tarazona (@tarazonanoelia) 's Twitter Profile Photo

📌New in ESMO Open: 🎯Tumor Boards can guide matched therapies for ESCAT II-III alterations. Patients had median OS 31 vs 11 months. 🏥Study conducted at INCLIVA GVA Sanitat, led by Desam Roda Valentina Gambardella 🔗sciencedirect.com/science/articl…

📌New in <a href="/ESMO_Open/">ESMO Open</a>: 🎯Tumor Boards can guide matched therapies for ESCAT II-III alterations. Patients had median OS 31 vs 11 months.

🏥Study conducted at <a href="/incliva_iis/">INCLIVA</a> <a href="/GVAsanitat/">GVA Sanitat</a>, led by <a href="/Desam_Roda/">Desam Roda</a> <a href="/ValeGambardella/">Valentina Gambardella</a> 

🔗sciencedirect.com/science/articl…
El Norte de Castilla (@nortecastilla) 's Twitter Profile Photo

El científico vallisoletano que investiga en Londres: «Cada tipo de cáncer es una enfermedad diferente» leer.elnortedecastilla.es/kjztj2